Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24.

Growth over the financial year was driven by increased sales in oncology, particularly in the United States.

Several partnership agreements in oncology and neurology strengthen the Group's R&D portfolio in rare diseases.

Achieving 2025 targets reflects successful transformation that began in 2015 and underpins the Group's ambitions for 2030.

SURESNES, France, Jan. 27, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, published its financial results for the 2024/25 financial year today and recapped the highlights that led to such significant growth.

Olivier Laureau, President of Servier, said: "The solid results from our 2024/25 financial year put us one important step closer to achieving our 2030 objectives. They validate the relevance of our differentiated innovation strategy to serve patients and the commitment of our employees. These results also underscore the success of the Group's transformation, which began 10 years ago, involving significant investments in innovation and international expansion. Our long-term vision is made possible by the fact that we are governed by a foundation."

Excerpt from the Group's audited results[1] (financial year ending September 30, 2025)

EUR Million

2024/25

2023/24

Evolution

Group Revenue

6,860

5,902

+16.2 %

  Brand-name business revenue

5,307

4,494

+18.1 %

  Generics business revenue

1,553

1,408

+10.3 %

Operating EBITDA

1,931

1,312

+47.2 %

  EBITDA margin

28.2 %

22.2 %

+6.0 pts

Recurring operating income

1,415

965

46.8 %

Net income

659

404

63.4 %

In the 2024/25 financial year, Group revenue reached €6.9 billion, exceeding the €6 billion target. This 16.2% increase over the previous year reflects the Group's growth momentum and ability to provide patients with an ever-increasing number of medicines.

Revenue growth resulted from a ...